# Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

> **NCT05290935** · PHASE2 · UNKNOWN · sponsor: **Lei Li** · enrollment: 122 (estimated)

## Conditions studied

- Recurrent Cervical Carcinoma
- Persistent Advanced Cervical Carcinoma
- Chemotherapy
- Immune Checkpoint Inhibitors
- Anti-PD-1 Antibody
- Albumin-bound Paclitaxel

## Interventions

- **DRUG:** Anti-PD-1 antibody camrelizumab
- **DRUG:** Albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT05290935
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-13
- **Primary completion:** 2022-12-13
- **Final completion:** 2024-03-13
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2022-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290935, "Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05290935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*